Lords Mark Industries Limited has secured a manufacturing license for its Biomesca Analytics Platform, becoming the first and only company in India to receive such approval for an In Vitro Diagnostic Software (Software as a Medical Device – SaMD). The license, granted under the Medical Devices Rules, 2017, positions the platform as a wellness and health-information tool designed for preventive healthcare and early health risk assessment. This regulatory milestone enables the company to commercialize gut microbiome science for mainstream wellness applications.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing, dated August 10, 2026, was submitted to the Manager – Listing Department at BSE Limited. The company, listed under Scrip code 501261, highlighted that the approval marks a significant step in integrating genomics with nutrition for personalized health insights.

Platform Capabilities and Classification

The Biomesca Analytics Platform combines whole metagenome sequencing data with a validated bioinformatics pipeline. It generates detailed gut microbiome profiles, including diversity scores, enterotype classification, and functional metabolic assessments. Based on these metrics, the platform provides evidence-based personalized dietary recommendations. The license classifies the software specifically for preventive healthcare purposes rather than diagnostic treatment.

Strategic Expansion Plans

Following the license receipt, Lord's Mark Industries plans to establish a nationwide network of Health & Wellness Centres. These centres will be set up in collaboration with hospitals, doctors, and healthcare institutions. The objective is to provide personalized microbiome assessments and preventive care strategies to a broader consumer base. The company aims to make these preventive healthcare solutions accessible, affordable, and impactful for millions of individuals across India.

Management Commentary

Sachidanand Upadhyay, Managing Director of Lord's Mark Industries Ltd., stated that healthcare is shifting from reactive treatment to proactive prevention. He emphasized that Biomesca represents a new era where genomics and nutrition converge to create truly personalized wellness. Through partnerships with medical professionals, the company intends to empower individuals with scientific health insights before disease develops.

What This Means for Investors

The receipt of the manufacturing license validates the technical and regulatory readiness of the Biomesca platform. As the first Indian entity to secure this specific SaMD classification under the Medical Devices Rules, 2017, Lord's Mark Industries holds a unique market position in the gut microbiome analytics segment. The planned expansion into a network of Health & Wellness Centres suggests a shift towards direct-to-consumer or provider-partnered service models, potentially creating new revenue streams beyond traditional product sales.

Lords Mark Industries Limited’s Board of Directors approved a two-step Minimum Public Shareholding (MPS) compliance scheme on August 6, 2026, comprising an Offer for Sale (OFS) by the Promoter Group and a Rights Issue open exclusively to public shareholders. This decision resolves the regulatory requirement to maintain the 25% public shareholding mandate under Rule 19A of the Securities Contracts (Regulation) Rules, 1957. The Board also appointed M/s. Nuvama Wealth Management Limited as the advisor to manage the capital restructuring and execution of these corporate actions. Additionally, CS Geeta Serwani was appointed as the Secretarial Auditor for FY25–26 to fill a casual vacancy.

The Board constituted a dedicated "MPS Committee" to oversee the seamless execution, operational management, and regulatory filings associated with the restructuring. This committee has been authorized to handle all procedural matters related to the OFS and Rights Issue, ensuring alignment with SEBI guidelines. The appointment of Nuvama Wealth Management Limited underscores the company’s intent to leverage specialized expertise for navigating the complex capital market instruments involved in this compliance exercise.

Regulatory Compliance and Governance

The approvals were granted in compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Secretarial Auditor appointment follows Section 204 of the Companies Act, 2013, and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. CS Geeta Serwani, Proprietor of M/s. Geeta Serwani & Associates, brings qualifications in B.Com, FCS, and LLB, with expertise in corporate governance and SEBI regulations.

Insider Trading Restrictions

The trading window for securities of Lords Mark Industries Limited remains closed for Designated Persons and their immediate relatives, in accordance with the company’s Code of Conduct under the SEBI (Prohibition of Insider Trading) Regulations, 2015. This restriction ensures that no material non-public information is misused while sensitive compliance decisions are finalized.

What the Numbers Show

The shift from exploring multiple options to approving a specific two-step mechanism indicates a decisive move toward regulatory compliance. By combining an OFS by promoters with a rights issue for the public, the company aims to boost public shareholding without diluting promoter control further through direct issuance. The involvement of Nuvama Wealth Management suggests a structured approach to managing investor relations and regulatory filings during this transition.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE567L01017/39643032-525e-4303-8eb1-e252756ab753.pdf